Loading...

We've got a brand new version of Simply Wall St! Try it out

Noxopharm

ASX:NOX
Snowflake Description

Worrying balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NOX
ASX
A$47M
Market Cap
  1. Home
  2. AU
  3. Pharmaceuticals & Biotech
Company description

Noxopharm Limited, a drug development company, focuses on the research and development of drugs to enhance radiotherapy in Australia and internationally. The last earnings update was 81 days ago. More info.


Add to Portfolio Compare Print
  • Noxopharm has significant price volatility in the past 3 months.
NOX Share Price and Events
7 Day Returns
-4%
ASX:NOX
4.7%
AU Biotechs
0.9%
AU Market
1 Year Returns
-31.4%
ASX:NOX
50.9%
AU Biotechs
16.3%
AU Market
NOX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Noxopharm (NOX) -4% -5.3% -10% -31.4% -30.8% -
AU Biotechs 4.7% 8.7% 20% 50.9% 168.8% 226.4%
AU Market 0.9% 1.9% 5.1% 16.3% 22.3% 22.5%
1 Year Return vs Industry and Market
  • NOX underperformed the Biotechs industry which returned 50.9% over the past year.
  • NOX underperformed the Market in Australia which returned 16.3% over the past year.
Price Volatility
NOX
Industry
5yr Volatility vs Market

Value

 Is Noxopharm undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Noxopharm is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Noxopharm has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Noxopharm. This is due to cash flow or dividend data being unavailable. The share price is A$0.36.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Noxopharm's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Noxopharm's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:NOX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in AUD A$-0.09
ASX:NOX Share Price ** ASX (2019-11-18) in AUD A$0.36
Global Biotechs Industry PE Ratio Median Figure of 145 Publicly-Listed Biotechs Companies 30.8x
Australia Market PE Ratio Median Figure of 519 Publicly-Listed Companies 18.63x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Noxopharm.

ASX:NOX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:NOX Share Price ÷ EPS (both in AUD)

= 0.36 ÷ -0.09

-3.91x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Noxopharm is loss making, we can't compare its value to the Global Biotechs industry average.
  • Noxopharm is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Noxopharm's expected growth come at a high price?
Raw Data
ASX:NOX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.91x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Global Biotechs Industry PEG Ratio Median Figure of 85 Publicly-Listed Biotechs Companies 1.39x
Australia Market PEG Ratio Median Figure of 347 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Noxopharm, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Noxopharm's assets?
Raw Data
ASX:NOX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in AUD A$0.00
ASX:NOX Share Price * ASX (2019-11-18) in AUD A$0.36
Australia Biotechs Industry PB Ratio Median Figure of 38 Publicly-Listed Biotechs Companies 3.17x
Australia Market PB Ratio Median Figure of 1,584 Publicly-Listed Companies 1.75x
ASX:NOX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:NOX Share Price ÷ Book Value per Share (both in AUD)

= 0.36 ÷ 0.00

-438.49x

* Primary Listing of Noxopharm.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Noxopharm has negative assets, we can't compare the value of its assets to the AU Biotechs industry average.

Next steps:

  1. Take a look at our analysis of NOX’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Noxopharm's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Noxopharm's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Noxopharm has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Noxopharm expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Noxopharm has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Noxopharm expected to grow at an attractive rate?
  • Unable to compare Noxopharm's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Noxopharm's earnings growth to the Australia market average as no estimate data is available.
  • Unable to compare Noxopharm's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ASX:NOX Future Growth Rates Data Sources
Data Point Source Value (per year)
Australia Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 13%
Australia Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 10.3%
Australia Market Earnings Growth Rate Market Cap Weighted Average 9.7%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:NOX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:NOX Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2019-11-18
ASX:NOX Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2019-06-30 4 -10 -11
2019-03-31 4 -9 -11
2018-12-31 3 -8 -11
2018-09-30 2 -9 -15
2018-06-30 1 -9 -18
2018-03-31 1 -7 -16
2017-12-31 1 -5 -14
2017-09-30 1 -4 -8
2017-06-30 0 -3 -3
2017-03-31 0 -3 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Noxopharm is high growth as no earnings estimate data is available.
  • Unable to determine if Noxopharm is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:NOX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Noxopharm Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:NOX Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2019-11-18
ASX:NOX Past Financials Data
Date (Data in AUD Millions) EPS *
2019-06-30 -0.09
2019-03-31 -0.09
2018-12-31 -0.09
2018-09-30 -0.13
2018-06-30 -0.17
2018-03-31 -0.16
2017-12-31 -0.15
2017-09-30 -0.10
2017-06-30 -0.04
2017-03-31 -0.03

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Noxopharm will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of NOX’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Noxopharm's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Noxopharm's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Noxopharm's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Noxopharm has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Noxopharm performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Noxopharm's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Noxopharm does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Noxopharm's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Noxopharm's 1-year growth to the Global Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Noxopharm's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Noxopharm Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:NOX Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 3.75 -11.22 9.35 6.25
2019-03-31 3.54 -10.98 8.85 5.47
2018-12-31 3.33 -10.75 8.34 4.70
2018-09-30 2.12 -14.52 7.34 4.40
2018-06-30 0.92 -18.28 6.33 4.11
2018-03-31 0.95 -16.09 5.22 3.46
2017-12-31 0.98 -13.90 4.11 2.82
2017-09-30 0.55 -8.47 3.24 1.82
2017-06-30 0.13 -3.05 2.38 0.82
2017-03-31 0.06 -2.70 2.15 0.61
2016-06-30 -1.06 0.83 0.21

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Noxopharm has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Noxopharm has efficiently used its assets last year compared to the Global Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Noxopharm improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Noxopharm's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Noxopharm has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Noxopharm's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Noxopharm's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Noxopharm's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Noxopharm has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Noxopharm's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Noxopharm has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Noxopharm Company Filings, last reported 4 months ago.

ASX:NOX Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 -1.45 3.93 2.91
2019-03-31 -1.45 3.93 2.91
2018-12-31 6.31 3.59 9.60
2018-09-30 6.31 3.59 9.60
2018-06-30 10.15 3.28 12.61
2018-03-31 10.15 3.28 12.61
2017-12-31 4.53 0.00 3.99
2017-09-30 4.53 0.00 3.99
2017-06-30 2.47 0.00 2.46
2017-03-31 2.47 0.00 2.46
2016-06-30 0.03 0.00 0.17
  • Noxopharm has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Noxopharm's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Noxopharm has less than a year of cash runway based on current free cash flow.
  • Noxopharm has less than a year of cash runway if free cash flow continues to grow at historical rates of 51.9% each year.
X
Financial health checks
We assess Noxopharm's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Noxopharm has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Noxopharm's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Noxopharm dividends.
If you bought A$2,000 of Noxopharm shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Noxopharm's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Noxopharm's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:NOX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 59 Stocks 2.1%
Australia Market Average Dividend Yield Market Cap Weighted Average of 390 Stocks 4%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.5%
Australia Bottom 25% Dividend Yield 25th Percentile 2.4%
Australia Top 25% Dividend Yield 75th Percentile 5.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ASX:NOX Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts
2019-11-18

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Noxopharm has not reported any payouts.
  • Unable to verify if Noxopharm's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Noxopharm's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Noxopharm has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Noxopharm's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Noxopharm afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Noxopharm has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Noxopharm's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Graham Kelly
COMPENSATION A$1,065,077
AGE 74
TENURE AS CEO 0.1 years
CEO Bio

Dr. Graham Edmund Kelly, B.Sc (Hons), B.VSc (Hons), Ph.D. is Chief Executive Officer at Noxopharm Limited since October, 2019. Dr. Kelly serves as an Executive Chairman of the Board at Noxopharm Limited since April 2019 and also its Founder and oversees the operations and strategic direction of Noxopharm Limited. Dr. Kelly served as a Chief Executive Officer of Noxopharm Group at Noxopharm Limited since 2019 until April 2019. Dr. Kelly serves as Non-independent Executive Director and President at Nyrada Inc. since July, 2019. Dr. Kelly has extensive corporate knowledge of Veyonda, experience in founding and overseeing the growth of 3 public biotech companies and his experience in having listed two companies on the Nasdaq exchange. He served as Group Chief Executive Officer since February 2019 and also served as Managing Director at Noxopharm Limited until April 2019. Dr. Kelly is responsible for Noxopharm and its subsidiary, Nyrada Inc., ahead of anticipated growing interest in both companies in both the Australian and U.S. investment markets and the global pharmaceutical industry. Dr. Kelly served as Chief Executive Officer until February 2019 at Noxopharm Limited. Dr. Kelly established Noxopharm Limited in order to commercialize NOX66 in 2015. He served as the Chief Executive Officer of Novogen Limited until July 22, 2015 and served as its Executive Chairman since December 7, 2012 until July 1, 2015. Dr. Kelly served as Scientific Advisor of Glycotex, Inc. He served as Phenoxodiol Program Director of Marshall Edwards, Inc. (now known as MEI Pharma, Inc.) and also served as its Chief Executive Officer. He served as Oncology Project Director of Marshall Edwards, Inc. and was responsible for the development of its investigational anti-cancer drug phenoxodiol. He served as Executive Chairman of Triaxial Pharmaceuticals Pty Ltd., since 2011. He founded Novogen Ltd., (formerly Norvet Ltd.) in 1992 and served as its First Managing Director. He served as an Executive Director of Novogen Limited since July 22, 2015 and previously served in the same position from 1994 to September 2, 2005. He served as President and Chief Executive Officer of Glycotex Inc., since September 2005. He has experience in anti-cancer drug development in general and idronoxil in particular, in the planning and conduct of clinical studies and in the management of public companies. Dr. Kelly developed the ß-1, 3-Glucan and Isoflavonoid compounds. He has spent nearly three decades in medical research involving drug development, immunology, surgery and cancer. He served as Executive Chairman of Marshall Edwards Inc. He served as Chairman of Marshall Edwards Inc. from 2000 to November 2006. He has served as the Chairman of Novogen Limited from March 1997 to December 31, 2000. He served as Chairman of Glycotex Inc., from May 1999 to September 2005. He serves as Director at Noxopharm Limited. He served as a Director at Marshall Edwards Inc. until May 2007. He has been an Adjunct Professor of the University of Sydney since May 2004. Dr. Kelly was a Senior Research Fellow in Experimental Surgery in the Faculty of Medicine at the University of Sydney from 1972 to 1994. After graduation he joined the newly-formed Department of Transplant Surgery in the Faculty of Medicine at The University of Sydney, gaining a Doctor of Philosophy in 1972. He graduated with degrees in Science (1968) and Veterinary Science (1969) from The University of Sydney.

CEO Compensation
  • Graham's compensation has increased whilst company is loss making.
  • Graham's remuneration is higher than average for companies of similar size in Australia.
Management Team Tenure

Average tenure of the Noxopharm management team in years:

0.6
Average Tenure
  • The average tenure for the Noxopharm management team is less than 2 years, this suggests a new team.
Management Team

Graham Kelly

TITLE
Founder
COMPENSATION
A$1M
AGE
74
TENURE
0.1 yrs

David Franks

TITLE
Company Secretary
COMPENSATION
A$7K
AGE
49
TENURE
2.8 yrs

Shawn Van Boheemen

TITLE
Chief Financial Officer
TENURE
0.6 yrs

Jeanette Bell

TITLE
Chief Operating Officer
TENURE
0.6 yrs

John Wilkinson

TITLE
Chief Scientific Officer
TENURE
1.8 yrs

Gisela Mautner

TITLE
Chief Medical Officer
TENURE
0.1 yrs

Greg Ambra

TITLE
Senior Vice-President of North American Operations
TENURE
0.1 yrs

Alex Hunter

TITLE
Chief Commercial Officer
Board of Directors Tenure

Average tenure of the Noxopharm board of directors in years:

0.6
Average Tenure
  • The average tenure for the Noxopharm board of directors is less than 3 years, this suggests a new board.
Board of Directors

Graham Kelly

TITLE
Founder
COMPENSATION
A$1M
AGE
74
TENURE
0.6 yrs

Peter Marks

TITLE
Non-Executive Deputy Chairman
COMPENSATION
A$208K
AGE
63
TENURE
0.6 yrs

Ian Dixon

TITLE
Non-Independent Non-Executive Director
COMPENSATION
A$90K
TENURE
3.7 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Noxopharm individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
12. Sep 19 Buy Graham Kelly Individual 09. Sep 19 10. Sep 19 53,263 A$0.36 A$19,063
10. Sep 19 Buy Graham Kelly Individual 04. Sep 19 06. Sep 19 11,737 A$0.36 A$4,250
21. Mar 19 Buy The Goodridge Family Trust Company 23. Nov 18 19. Mar 19 5,444,684 A$0.52 A$2,124,990
13. Feb 19 Buy Graham Kelly Individual 08. Feb 19 13. Feb 19 65,553 A$0.42 A$27,277
X
Management checks
We assess Noxopharm's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Noxopharm has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

What You Should Know About Noxopharm Limited's (ASX:NOX) Financial Strength

With current liabilities at AU$4.8m, the company has been able to meet these commitments with a current assets level of AU$11m, leading to a 2.22x current account ratio. … The current ratio is calculated by dividing current assets by current liabilities. … Next Steps: Although NOX’s debt level is towards the higher end of the spectrum, its cash flow coverage seems adequate to meet obligations which means its debt is being efficiently utilised.

Simply Wall St -

Investors Who Bought Noxopharm (ASX:NOX) Shares A Year Ago Are Now Down 52%

And unfortunately for Noxopharm Limited (ASX:NOX) shareholders, the stock is a lot lower today than it was a year ago. … Shareholders have had an even rougher run lately, with the share price down 12% in the last 90 days. … With just AU$3,325,353 worth of revenue in twelve months, we don't think the market considers Noxopharm to have proven its business plan.

Simply Wall St -

How Much Of Noxopharm Limited (ASX:NOX) Do Insiders Own?

Noxopharm is not a large company by global standards. … Our analysis of the ownership of the company, below, shows that. … institutions don't own many shares in the company

Simply Wall St -

Did Noxopharm Limited (ASX:NOX) Insiders Sell Shares?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. … As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.'. … In the last twelve months, the biggest single sale by an insider was when David Hannon sold AU$91k worth of shares at a price of AU$0.63 per share.

Simply Wall St -

What Kind Of Investor Owns Most Of Noxopharm Limited (ASX:NOX)?

Every investor in Noxopharm Limited (ASX:NOX) should be aware of the most powerful shareholder groups. … Taking a look at the our data on the ownership groups (below), it's seems that. … Let's take a closer look to see what the different types of shareholder can tell us about NOX

Simply Wall St -

Are Noxopharm Limited's (ASX:NOX) Interest Costs Too High?

Noxopharm Limited (ASX:NOX), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … However, the trade-off is NOX will have to follow strict debt obligations which will reduce its financial flexibility. … Is NOX growing fast enough to value financial flexibility over lower cost of capital

Simply Wall St -

Company Info

Description

Noxopharm Limited, a drug development company, focuses on the research and development of drugs to enhance radiotherapy in Australia and internationally. It primarily develops Veyonda, an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also focuses on developing NYX-330, a PCSK9-inhibitor and LDL-cholesterol-lowering drug; NYX-104, a neuroprotectant that protects the brain from further damage after stroke and traumatic brain injury; and NYX-205, an anti-inflammatory drug for the treatment of nerve tissue inflammation. In addition, it develops anti-autoimmune drugs, such as IRAK4 and TPL2 inhibitors. Noxopharm Limited was incorporated in 2015 and is based in Gordon, Australia.

Details
Name: Noxopharm Limited
NOX
Exchange: ASX
Founded: 2015
A$46,708,906
127,969,607
Website: http://www.noxopharm.com
Address: Noxopharm Limited
828 Pacific Highway,
Suite 3,
Gordon,
New South Wales, 2072,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX NOX Ordinary Shares Australian Securities Exchange AU AUD 09. Aug 2016
CHIA NOX Ordinary Shares Chi-X Australia AU AUD 09. Aug 2016
Number of employees
Current staff
Staff numbers
0
Noxopharm employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/18 10:43
End of day share price update: 2019/11/18 00:00
Last estimates confirmation: 2019/05/23
Last earnings filing: 2019/08/29
Last earnings reported: 2019/06/30
Last annual earnings reported: 2019/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.